| scholarly article | Q13442814 |
| P50 | author | Jesús Prieto | Q28324697 |
| Paulette Bioulac-Sage | Q43376282 | ||
| Carmen Berasain | Q39790214 | ||
| P2093 | author name string | Maria I Demartis | |
| Charles Balabaud | |||
| Francesco Feo | |||
| Rosa M Pascale | |||
| Jordi Muntané | |||
| Raquel Urtasun | |||
| Maria U Latasa | |||
| Maria Azcona | |||
| Maria Elizalde | |||
| Matias A Avila | |||
| Oihane Garcia-Irigoyen | |||
| Saioa Goñi | |||
| Stella Balzani | |||
| P2860 | cites work | Proapoptotic kinase MST2 coordinates signaling crosstalk between RASSF1A, Raf-1, and Akt | Q24296477 |
| Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control | Q24299106 | ||
| TEAD mediates YAP-dependent gene induction and growth control | Q24336045 | ||
| Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach | Q24633776 | ||
| Upregulation of the amino acid transporter ATB0,+ (SLC6A14) in colorectal cancer and metastasis in humans | Q28251733 | ||
| Hepatocellular carcinoma: epidemiology and molecular carcinogenesis | Q28306363 | ||
| Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. | Q39899643 | ||
| Expression of multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin | Q39909012 | ||
| Down-regulation of connective tissue growth factor by inhibition of transforming growth factor beta blocks the tumor-stroma cross-talk and tumor progression in hepatocellular carcinoma. | Q39939616 | ||
| The epidermal growth factor receptor ligand amphiregulin participates in the development of mouse liver fibrosis. | Q39960326 | ||
| Reversal of drug resistance of hepatocellular carcinoma cells by adenoviral delivery of anti-ABCC2 antisense constructs | Q40092607 | ||
| Connexin 43 expression promotes malignancy of HuH7 hepatocellular carcinoma cells via the inhibition of cell-cell communication | Q40175099 | ||
| Underexpressed coactivators PGC1alpha and SRC1 impair hepatocyte nuclear factor 4 alpha function and promote dedifferentiation in human hepatoma cells. | Q40246865 | ||
| Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells. | Q40267021 | ||
| Expression of taurine transporter is regulated through the TonE (tonicity-responsive element)/TonEBP (TonE-binding protein) pathway and contributes to cytoprotection in HepG2 cells | Q40556250 | ||
| Association of Vimentin overexpression and hepatocellular carcinoma metastasis | Q40612642 | ||
| Connective tissue growth factor gene regulation. Requirements for its induction by transforming growth factor-beta 2 in fibroblasts | Q42805569 | ||
| The Significance of Fibroblast Growth Factor Receptor 2 Expression in Differentiation of Hepatocellular Carcinoma | Q43451322 | ||
| Thrombin-induced connective tissue growth factor expression in human lung fibroblasts requires the ASK1/JNK/AP-1 pathway. | Q45983849 | ||
| Connective tissue growth factor is a Smad2 regulated amplifier of transforming growth factor beta actions in hepatocytes--but without modulating bone morphogenetic protein 7 signaling. | Q51753112 | ||
| Stromal cell-derived factor-1/chemokine (C-X-C motif) ligand 12 stimulates human hepatoma cell growth, migration, and invasion. | Q54559632 | ||
| Evidence for the Decreased Expression of the Latent TGF-β Binding Protein and its Splice Form in Human Liver Tumours | Q59480296 | ||
| Membrane and morphological changes in apoptotic cells regulated by caspase-mediated activation of PAK2 | Q73386407 | ||
| Significance of serum connective tissue growth factor in patients with hepatocellular carcinoma and relationship with angiogenesis | Q84329978 | ||
| Molecular classification of hepatocellular carcinoma | Q84403214 | ||
| YAP1 increases organ size and expands undifferentiated progenitor cells | Q28592519 | ||
| Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma | Q33611696 | ||
| YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway | Q33644875 | ||
| MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties. | Q34103666 | ||
| The CCN family: a new class of inflammation modulators? | Q34153304 | ||
| Expressions of cysteine-rich61, connective tissue growth factor and Nov genes in hepatocellular carcinoma and their clinical significance | Q36076333 | ||
| Deregulation of FoxM1b leads to tumour metastasis | Q36108360 | ||
| Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy | Q36914691 | ||
| Altered EGFR localization and degradation in human breast cancer cells with an amphiregulin/EGFR autocrine loop. | Q37077594 | ||
| Regulation and function of connective tissue growth factor/CCN2 in tissue repair, scarring and fibrosis | Q37115997 | ||
| To kill a tumor cell: the potential of proapoptotic receptor agonists | Q37181734 | ||
| Susceptibility to liver fibrosis in mice expressing a connective tissue growth factor transgene in hepatocytes | Q37331302 | ||
| The epidermal growth factor receptor: a link between inflammation and liver cancer. | Q37476452 | ||
| Targeting YAP and Hippo signaling pathway in liver cancer | Q37764854 | ||
| The role of signaling pathways in the development and treatment of hepatocellular carcinoma | Q37773788 | ||
| A new regulator of the cell cycle: the PR-Set7 histone methyltransferase | Q37825723 | ||
| Disruption of the latent transforming growth factor-beta binding protein-1 gene causes alteration in facial structure and influences TGF-beta bioavailability | Q38297165 | ||
| Ethanol-stimulated differentiated functions of human or mouse hepatic stellate cells are mediated by connective tissue growth factor | Q39620314 | ||
| Amphiregulin induces the alternative splicing of p73 into its oncogenic isoform DeltaEx2p73 in human hepatocellular tumors. | Q39815229 | ||
| Expression, Cellular Distribution, and Prognostic Relevance of TRAIL Receptors in Hepatocellular Carcinoma | Q39831266 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatocellular carcinoma | Q1148337 |
| connective tissue | Q25615 | ||
| P304 | page(s) | 2149-2158 | |
| P577 | publication date | 2011-12-01 | |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | Connective tissue growth factor autocriny in human hepatocellular carcinoma: oncogenic role and regulation by epidermal growth factor receptor/yes-associated protein-mediated activation | |
| P478 | volume | 54 |
| Q53826807 | A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma. |
| Q39172217 | A potential autocrine role for interferon tau in ovine trophectoderm |
| Q36743804 | Activin A-Smad Signaling Mediates Connective Tissue Growth Factor Synthesis in Liver Progenitor Cells |
| Q38823799 | CIZ1 is upregulated in hepatocellular carcinoma and promotes the growth and migration of the cancer cells |
| Q37622617 | Cluster of differentiation 166 (CD166) regulated by phosphatidylinositide 3-Kinase (PI3K)/AKT signaling to exert its anti-apoptotic role via yes-associated protein (YAP) in liver cancer. |
| Q38514410 | Control of Proliferation and Cancer Growth by the Hippo Signaling Pathway |
| Q54356882 | Cytoplasmic YAP expression is associated with prolonged survival in patients with lung adenocarcinomas and epidermal growth factor receptor tyrosine kinase inhibitor treatment. |
| Q37162642 | Decreased expression of connective tissue growth factor in non-small cell lung cancer is associated with clinicopathological variables and can be restored by epigenetic modifiers. |
| Q90323427 | Down-regulation of interferon regulatory factor 2 binding protein 2 suppresses gastric cancer progression by negatively regulating connective tissue growth factor |
| Q43651454 | Dual roles of yes-associated protein (YAP) in colorectal cancer |
| Q26771265 | EGFR Signaling in Liver Diseases |
| Q49958316 | EGFR-PI3K-PDK1 pathway regulates YAP signaling in hepatocellular carcinoma: the mechanism and its implications in targeted therapy. |
| Q37672884 | Elevated YAP and its downstream targets CCN1 and CCN2 in basal cell carcinoma: impact on keratinocyte proliferation and stromal cell activation. |
| Q39252001 | Epidermal growth factor receptor signaling in hepatocellular carcinoma: inflammatory activation and a new intracellular regulatory mechanism. |
| Q41260004 | Functional genomics screen identifies YAP1 as a key determinant to enhance treatment sensitivity in lung cancer cells |
| Q42564794 | Hedgehog regulates yes-associated protein 1 in regenerating mouse liver |
| Q42784235 | Hepatocyte ERBB3 and EGFR are required for maximal CCl4-induced liver fibrosis |
| Q89710826 | Hepatocyte nuclear factor 4α negatively regulates connective tissue growth factor during liver regeneration |
| Q64275574 | High Risk of Hepatocellular Carcinoma Development in Fibrotic Liver: Role of the Hippo-YAP/TAZ Signaling Pathway |
| Q58576706 | Huaier Augmented the Chemotherapeutic Sensitivity of Oxaliplatin via Downregulation of YAP in Hepatocellular Carcinoma |
| Q38944998 | Ileal FGF15 contributes to fibrosis-associated hepatocellular carcinoma development |
| Q37141152 | Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells |
| Q47834790 | Low angiomotin-p130 with concomitant high Yes-associated protein 1 expression is associated with adverse prognosis of advanced gastric cancer |
| Q55516291 | Lysyl oxidase: A colorectal cancer biomarker of lung and hepatic metastasis. |
| Q24339513 | MEK1 promotes YAP and their interaction is critical for tumorigenesis in liver cancer |
| Q36953540 | Melanoma cell adhesion molecule stimulates yes-associated protein transcription by enhancing CREB activity via c-Jun/c-Fos in hepatocellular carcinoma cells |
| Q34138366 | MiR-506 suppresses proliferation of hepatoma cells through targeting YAP mRNA 3'UTR. |
| Q38901007 | MicroRNA-26b inhibits metastasis of osteosarcoma via targeting CTGF and Smad1. |
| Q39175087 | Mutual interaction between YAP and CREB promotes tumorigenesis in liver cancer |
| Q36273267 | NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition |
| Q52674242 | Novel candidate genes important for asthma and hypertension comorbidity revealed from associative gene networks. |
| Q38371893 | Overexpression of Yes-associated protein and its association with clinicopathological features of hepatocellular carcinoma: A meta-analysis |
| Q37580201 | Post-translational deregulation of YAP1 is genetically controlled in rat liver cancer and determines the fate and stem-like behavior of the human disease. |
| Q49918430 | Proliferation of hepatic stellate cells, mediated by YAP and TAZ, contributes to liver repair and regeneration after liver ischemia/reperfusion injury |
| Q28484499 | Regulation of amphiregulin gene expression by β-catenin signaling in human hepatocellular carcinoma cells: a novel crosstalk between FGF19 and the EGFR system |
| Q38531851 | Regulation of hepatocyte identity and quiescence. |
| Q52345488 | Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight. |
| Q39173436 | SIRT1 regulates YAP2-mediated cell proliferation and chemoresistance in hepatocellular carcinoma |
| Q39016331 | Serine protease inhibitor Kazal type 1 promotes epithelial-mesenchymal transition through EGFR signaling pathway in prostate cancer |
| Q38799990 | Splicing regulator SLU7 preserves survival of hepatocellular carcinoma cells and other solid tumors via oncogenic miR-17-92 cluster expression |
| Q33591632 | TGF-β-independent CTGF induction regulates cell adhesion mediated drug resistance by increasing collagen I in HCC |
| Q38259755 | Targeting CTGF, EGF and PDGF pathways to prevent progression of kidney disease. |
| Q38169563 | The EGFR signalling system in the liver: from hepatoprotection to hepatocarcinogenesis |
| Q41225471 | The GSK3β inhibitor BIS I reverts YAP-dependent EMT signature in PDAC cell lines by decreasing SMADs expression level. |
| Q38903548 | The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer |
| Q91830517 | The YAP signaling pathway promotes the progression of lymphatic malformations through the activation of lymphatic endothelial cells |
| Q37108727 | The hippo-yes association protein pathway in liver cancer |
| Q38904795 | The membrane protein melanoma cell adhesion molecule (MCAM) is a novel tumor marker that stimulates tumorigenesis in hepatocellular carcinoma. |
| Q42164554 | The pan-deacetylase inhibitor panobinostat modulates the expression of epithelial-mesenchymal transition markers in hepatocellular carcinoma models |
| Q55022572 | The role of Hippo signal pathway in breast cancer metastasis. |
| Q38151262 | The therapeutic potential of bone marrow-derived mesenchymal stromal cells on hepatocellular carcinoma. |
| Q27025661 | The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment |
| Q55500782 | Three Dimensional Mixed-Cell Spheroids Mimic Stroma-Mediated Chemoresistance and Invasive Migration in hepatocellular carcinoma. |
| Q36237330 | YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14. |
| Q35911150 | YAP oncogene overexpression supercharges colon cancer proliferation |
| Q54977387 | YAP/TAZ Activation as a Target for Treating Metastatic Cancer. |
| Q36881080 | Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma |
| Q48171440 | miR-375 is involved in Hippo pathway by targeting YAP1/TEAD4-CTGF axis in gastric carcinogenesis |
Search more.